The Antiplatelet Drugs Market provides essential medicines used to prevent blood clots in cardiovascular patients. Antiplatelet drugs like clopidogrel, ticagrelor, prasugrel, etc. inhibit platelet aggregation and prevent formation of thrombus, reducing the risk of heart attacks and strokes. With rising cardiovascular diseases worldwide, the demand for antiplatelet drugs continues to grow significantly.
Market Overview:
Antiplatelet drugs act as blood thinners by inhibiting platelet aggregation. They are primarily used after procedures like angioplasty and stenting to prevent re-narrowing of arteries. These drugs reduce morbidity and mortality in patients with conditions like acute coronary syndrome, previous heart attack or stroke. The market has witnessed significant growth due to the growing aging population and increasing prevalence of cardiovascular diseases globally.
Market key trends:
The Global Antiplatelet Drugs Market Size is estimated to witness high growth owing to rising geriatric population. Older adults suffer more frequently from cardiovascular issues like heart attacks, strokes, and peripheral artery disease, driving the need for antiplatelet therapy. Moreover, sedentary lifestyle and changing dietary patterns have led to significant rise in obesity, diabetes and hypertension - key risk factors for cardiovascular ailments. Growing awareness about benefits of antiplatelet drugs in secondary cardiovascular prevention is also contributing to the increased demand. Manufacturers are further investing in developing enhanced formulations with better patient compliance.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate as R&D and clinical trials require huge investments and regulatory approvals are stringent in pharmaceutical industry.
Bargaining power of buyers: The bargaining power of buyers is high as antiplatelet drugs market is competitive with presence of many generic manufacturers. Buyers can negotiate on price easily.
Bargaining power of suppliers: The bargaining power of suppliers is low due to availability of many suppliers for raw materials. Suppliers do not have control over pricing.
Threat of new substitutes: The threat of new substitutes is low as there are limited substitutes available for antiplatelet drugs in treatment of cardiovascular diseases.
Competitive rivalry: Market is dominated by top players with huge R&D investments.
SWOT Analysis
Strength: High prevalence of cardiovascular diseases, strong product pipeline.
Weakness: Patent expiries of blockbuster drugs, pricing pressure due to generics.
Opportunity: Emerging economies with large patient pool, new indications.
Threats: Stringent regulations, reimbursement cuts.
Key Takeaways
The global antiplatelet drugs market is expected to witness high growth at a CAGR of 7.8% over the forecast period, due to increasing prevalence of cardiovascular diseases. Asia Pacific region is expected to grow at fastest pace owing to large population base and improved access to healthcare facilities in emerging economies like India and China.
Regional analysis - North America dominated global antiplatelet drugs market in 2023 and is expected to retain its dominance during the forecast period. However, Asia Pacific region is anticipated to witness highest growth rate over the next few years on account of increasing healthcare spending and presence of generic players.
Key players - Key players operating in the antiplatelet drugs market are AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., Eli Lilly and Company, Merck & Co., Inc., Otsuka Pharmaceutical Company, Ltd., Sanofi, and The Medicines Company. These players are adopting strategies like new launches, expansions and collaborations to strengthen their market position.
Read Our More Blogs : https://www.dailyprbulletin.com/antiplatelet-drugs-market-forecast-outlook-trend-2023-2030/
Sign in to leave a comment.